LaFleur & Godfrey LLC Decreases Stake in DENTSPLY SIRONA Inc. (XRAY)

LaFleur & Godfrey LLC decreased its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 9.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 48,093 shares of the medical instruments supplier’s stock after selling 5,125 shares during the quarter. LaFleur & Godfrey LLC’s holdings in DENTSPLY SIRONA were worth $2,876,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of XRAY. Commonwealth Bank of Australia grew its holdings in DENTSPLY SIRONA by 19.0% in the second quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock valued at $104,000 after purchasing an additional 260 shares during the last quarter. Acrospire Investment Management LLC acquired a new stake in DENTSPLY SIRONA in the second quarter valued at $113,000. Dupont Capital Management Corp acquired a new stake in DENTSPLY SIRONA in the second quarter valued at $116,000. Korea Investment CORP grew its holdings in DENTSPLY SIRONA by 139.9% in the second quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock valued at $139,000 after purchasing an additional 1,251 shares during the last quarter. Finally, Huntington National Bank acquired a new stake in DENTSPLY SIRONA in the third quarter valued at $157,000. 94.65% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “LaFleur & Godfrey LLC Decreases Stake in DENTSPLY SIRONA Inc. (XRAY)” was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://weekherald.com/2017/11/14/lafleur-godfrey-llc-has-2-88-million-stake-in-dentsply-sirona-inc-xray.html.

DENTSPLY SIRONA Inc. (NASDAQ XRAY) traded up $0.22 during trading on Tuesday, hitting $65.80. The stock had a trading volume of 2,055,700 shares, compared to its average volume of 1,646,720. The stock has a market cap of $15,020.00, a P/E ratio of 26.13, a price-to-earnings-growth ratio of 2.60 and a beta of 1.27. The company has a current ratio of 2.32, a quick ratio of 1.59 and a debt-to-equity ratio of 0.21. DENTSPLY SIRONA Inc. has a 52 week low of $52.53 and a 52 week high of $67.95.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Friday, November 3rd. The medical instruments supplier reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business posted $0.66 EPS. analysts expect that DENTSPLY SIRONA Inc. will post 2.66 EPS for the current fiscal year.

In other DENTSPLY SIRONA news, insider Mark Thierer acquired 77,000 shares of the stock in a transaction on Monday, November 13th. The stock was purchased at an average price of $66.04 per share, for a total transaction of $5,085,080.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Nicholas W. Alexos acquired 50,000 shares of the stock in a transaction on Monday, November 13th. The shares were acquired at an average price of $65.85 per share, with a total value of $3,292,500.00. The disclosure for this purchase can be found here. Company insiders own 1.99% of the company’s stock.

XRAY has been the topic of several research reports. BidaskClub lowered DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Morgan Stanley reaffirmed an “overweight” rating and set a $69.00 price objective (up previously from $67.00) on shares of DENTSPLY SIRONA in a research note on Friday, October 6th. Zacks Investment Research lowered DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Cleveland Research lowered DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a research note on Thursday, October 5th. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of DENTSPLY SIRONA in a research note on Thursday, October 19th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. DENTSPLY SIRONA has a consensus rating of “Hold” and a consensus target price of $67.00.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply